Fully approved and scalable patient digitisation platform enables unprecedented Insights into the clinical status of one or hundreds of patients
Isansys Lifecare Limited, the provider of complete real-time physiological patient data services and systems, today announces the general availability of its CE-marked Patient Status Engine™ – the world’s first plug-and-play continuous wireless vital signs monitoring system complete with clinical apps that can be customised for individual needs. The Patient Status Engine (PSE) achieved its CE mark for both the monitoring technology and associated portal for presentation of the clinical data, making the complete system a fully certified medical device. The approved patient digitisation platform is being deployed in a number of leading hospitals and is now commercially available to enable unprecedented insights into the clinical status of one, or hundreds, of patients. As a fully integrated and uniquely scalable device and IT platform, the PSE may even be deployed independently of existing IT systems. For the first time, clinicians and researchers can begin full-scale deployments or clinical and investigatory programmes incorporating their own ideas and clinical apps intuitively, easily and within minutes of taking delivery of their first PSE kit. You can watch a video overview of the end-to-end PSE system on the Isansys homepage now at http://www.isansys.com.
The Patient Status Engine is more than a wireless vital sign monitoring system. An approved plug-and-play clinical platform, the PSE continuously collects multiple vital sign data, simply, securely and straight out of the box. It analyses and delivers the status of any number of patients in real-time, to any location. The system incorporates the Isansys LifeTouch cardiac monitor – a lightweight and unobtrusive smart patch that collects data directly from the patient and analyses every heartbeat to provide continuous heart rate, respiration rate and heart rate variability. It also includes a remotely triggerable ECG visualization function for set-up and verification that may also be used as an event marker. The LifeTouch is the world’s first cloud-ready medical device of its kind, and the first to be certified as a Class IIa medical device under the European Medical Device Directive (MDD).
With a wireless pulse oximeter and blood pressure monitor, a patient’s physiology is automatically uploaded as a series of secure digital files to a patient record and may be accessed on any authorised computer, tablet or smart phone. The PSE kit also comes pre-bundled with several apps, such as patient charting, early warning scores and real-time HRV plots, useful for the determination of autonomic function. In an industry first, the PSE offers clinicians and researchers the ability to deploy their own unique apps to aid clinical discovery, adverse event prevention and the generation of big data sets. In addition the PSE has an API that presents the “digitised patient” on an interface that may be opened for straightforward integration into other hospital information systems, electronic health records or digital health clouds.
Commenting on the announcement, Isansys Lifecare CEO Keith Errey said: “With the Patient Status Engine, we are not simply providing a technology solution to healthcare providers – we are putting a unique tool into the hands of practising clinicians and clinical researchers and giving them the ability to define how it can best benefit their patients. At this moment, we are working for clinicians and healthcare specialists who are seeing extraordinary results by combining their insight and experience with this new and exceptionally powerful digital knowledge of their patients.”
Rebecca Weir, Isansys Director of Business Development added: “Unlocking the meaning in this newly available data is leading to discoveries, creating apps that are providing a completely new understanding of the changes and trends in the clinical status of patients. With today’s general availability of the PSE system, Isansys is ready to support the full spectrum of clinical use – from clinicians buying a single device for investigation, through to a hospital monitoring hundreds of patients and wanting to develop unique apps customised to patients’ needs.”